Latest news for Netcapital (NASDAQ:NCPLW) Stock

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

Netcapital Inc

Investors love high-growth stories, and they should.
Companies that are growing rapidly have the potential to deliver massive gains.
The problem is that Wall Street and most observers are not always using the right metrics to determine growth.
The most used metric is earnings per share growth. Nothing excites people more than a massive year-over-year earnings gain.
Once you have been at this for a while, you realize that a competent accountant can make the earnings per share numbers be almost anything their boss wants them to be.
Earnings management and even outright fraud can go on for longer than one would think.
Just as with people who bought into Enron, WorldCom, or any other companies that were Wall Street darlings until the ugly truth was revealed.
Many companies have been accused of other forms of accounting misconduct that led investors down a primrose path over the years, including stalwarts like Kraft Heinz (Ticker: KHC), Chemours Chemical (Ticker: CC) (Teflon manufacturer), and Archer Daniels Midland (Ticker: ADM), which have been accused of irregularities that made things look better than they were.
I tend to ignore reported earnings most of the time.
One of the greatest lessons I have learned over the years is that everything eventually shows up on the balance sheet.
I like to look at top-line revenue growth and then skip everything in between to look at book value growth.
This allows me to see what happens once management gets their hands on the money.
Did they use the cash wisely and invest the excess cash flow to increase the company&#8217;s value?
Or did they waste it and not create much value along the way?
If you want to see this theory in action, the three companies with the fastest book value growth in the S&amp;P 500(Ticker: SPY) are NVIDIA (Ticker: NVDA), Amazon (Ticker: AMZN), and Tesla (Ticker: TSLA).
Management received the cash, paid the bills, and grew the value of the business.
In this case, it does not matter what the price-to-book ratio value is.
We are not measuring valuations.
We are simply determining if management is converting revenues to real value at a high rate.
It is no accident that Warren Buffett has measured his success at Berkshire Hathaway (BRK.A) by the growth in book value.
It is the best way to measure growth.
Very few people look at stocks this way, so we can use the combination of revenue and book value growth to find some potential gems that are well under Wall Street&#8217;s radar.
Velocity Financial (Ticker: VEL) is a business that is perfectly positioned to take advantage of the housing affordability crisis.
Thanks to higher mortgage rates and a lack of inventory, people are renting for longer.
Velocity Financial (VEL) operates in an often-overlooked but highly lucrative niche of the real estate finance world, specializing in loans for real estate investors. This is not your typical Fannie Mae or Freddie Mac lending operation; Velocity thrives in the non-QM (non-qualified mortgage) space, targeting small- to mid-sized investors who need financing for rental properties and small commercial ventures. This is the bread and butter of the real estate world—the individuals who are rehabbing houses, growing rental portfolios, and breathing life into small business properties.
Velocity is not competing with big banks or institutions chasing the cookie-cutter borrower. Instead, it is laser-focused on a niche that is too small for the big institutions to care about but too complex for the smaller entities to handle. It offers tailored financing for single-family rentals, small multifamily properties, and even small commercial buildings like retail or mixed-use spaces. Borrowers are often small investors with solid property cash flow but not the financial profile big banks want to consider.
The loans are short- to medium-term, high-yield, and relatively low balance, which means Velocity captures some attractive interest income compared to traditional lenders. Velocity has built a scalable origination platform, using brokers and direct relationships to keep the deals flowing while maintaining tight underwriting standards. Their proprietary process focuses on the property&#8217;s cash flow, an approach that fits this market perfectly.
The business is growing impressively.
Revenue is growing at over 20% annually, and tangible book value has grown by about 25% over the past five years.
Given the niche market Velocity serves, I would expect the company to continue to grow at an above-average rate for several years. As Wall Street discovers this company, we could see buying pressure push the stock to much higher prices in the years ahead.
Red Violet, Inc. (Ticker: RDVT) is one of those under-the-radar plays that quietly builds an impressive moat in a high-growth niche. At its core, this is a data and technology company with a focus on identity intelligence and data fusion. In simpler terms, Red Violet takes massive amounts of data, turns it into actionable insights, and sells it to industries that need help solving some of their biggest problems—fraud, compliance, risk, and verification.
This is the kind of company that thrives in today&#8217;s data-driven world. It is not flashy, but it is indispensable to its customers. Red Violet operates through two key platforms: IDI Core and Forewarn, both of which are designed to make the complex world of data analytics simple and accessible for its users.
IDI Core is the workhorse of the operation. This platform is used by a variety of industries—financial services, insurance, government, legal—to verify identities, detect fraud, and conduct investigations. Think of it as the Swiss Army knife for anyone needing to sift through mountains of data quickly and accurately. It is the platform that makes businesses smarter, faster, and more compliant in an increasingly regulated world.
Then there is Forewarn, which takes a different tack by focusing on the real estate industry. Real estate agents use this tool to screen potential clients and assess risks instantly. With safety concerns on the rise in the field, Forewarn has carved out a strong niche in a growing vertical.
What sets Red Violet apart is its proprietary technology. They have built a scalable infrastructure capable of analyzing billions of records and turning them into something useful.
That is not just tech buzz. It is the foundation for why customers keep coming back and why the company&#8217;s business model works.
Sales and earnings are both growing at around 30% a year and have the potential to continue to grow at a very high rate.
As the dollars come in the door, Red Violet Management is using them to increase the value of the company at a rapid pace.

Opinion

AMZN

NVDA

RDVT

TSLA

Under the Radar: The Importance of Book Value Growth in Assessing Company Stability

Starwood Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $21.25, a high estimate of $23.00, and a low estimate of $20.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.71%. 
<img src="https://www.benzinga.com/files/images/story/2025/1736884865_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Starwood Prop Trust. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$22.50</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$19.50</td>
</tr>
<tr>
<td>Steven Delaney</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$20.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Starwood Prop Trust. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Starwood Prop Trust compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Starwood Prop Trust's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Starwood Prop Trust's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STWD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Starwood Prop Trust analyst ratings.</a>
<h2>Get to Know Starwood Prop Trust Better</h2>
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment and Investing and Servicing Segment. The company generates the majority of its revenue from the Real estate commercial and residential lending segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
<h3>Unraveling the Financial Story of Starwood Prop Trust</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Starwood Prop Trust displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 53.5%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Starwood Prop Trust's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 31.76%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Starwood Prop Trust's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.17%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Starwood Prop Trust's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.12%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.34, Starwood Prop Trust adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

STWD

Where Starwood Prop Trust Stands With Analysts

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Hartford Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $134.17, a high estimate of $141.00, and a low estimate of $125.00. This upward trend is apparent, with the current average reflecting a 6.76% increase from the previous average price target of $125.67.
<img src="https://www.benzinga.com/files/images/story/2025/1736884854_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Hartford Finl Servs Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$141.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Hartford Finl Servs Gr. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Hartford Finl Servs Gr compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Hartford Finl Servs Gr's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Hartford Finl Servs Gr's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HIG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hartford Finl Servs Gr analyst ratings.</a>
<h2>All You Need to Know About Hartford Finl Servs Gr</h2>
The Hartford Financial Services Group Inc offers a diverse range of property and casualty insurance, group benefits, and mutual fund services to a customer base of individuals and corporations. It operates in five segments: Commercial Lines, Personal Lines, Property &amp; Casualty Other Operations, Group Benefits, and Hartford Funds, as well as a Corporate category.
<h3>Hartford Finl Servs Gr's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Hartford Finl Servs Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.05% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Hartford Finl Servs Gr's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 11.33%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Hartford Finl Servs Gr's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.75%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Hartford Finl Servs Gr's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.95%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.26.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Hartford Finl Servs Gr Through 6 Analysts

Payoneer Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $12.3, a high estimate of $14.00, and a low estimate of $10.00. Surpassing the previous average price target of $10.25, the current average has increased by 20.0%.
<img src="https://www.benzinga.com/files/images/story/2025/1736884846_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Payoneer Global's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$8.50</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$13.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Will Nance</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Payoneer Global. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Payoneer Global compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Payoneer Global's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Payoneer Global's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PAYO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Payoneer Global analyst ratings.</a>
<h2>Discovering Payoneer Global: A Closer Look</h2>
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started to empower global commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
<h3>Key Indicators: Payoneer Global's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Payoneer Global's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 19.34%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Payoneer Global's net margin is impressive, surpassing industry averages. With a net margin of 16.75%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Payoneer Global's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 5.95%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Payoneer Global's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.6%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.05, Payoneer Global adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PAYO

Expert Outlook: Payoneer Global Through The Eyes Of 10 Analysts

13 analysts have shared their evaluations of Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Evolent Health and provided 12-month price targets. The average target is $21.08, accompanied by a high estimate of $34.00 and a low estimate of $15.00. A decline of 32.39% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1736884839_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Evolent Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Evolent Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Evolent Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Evolent Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evolent Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Evolent Health's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Evolent Health showcased positive performance, achieving a revenue growth rate of 21.6% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Evolent Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.03% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Evolent Health's ROE stands out, surpassing industry averages. With an impressive ROE of -2.99%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Evolent Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.61, Evolent Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Evolent Health Stock

Investors with a lot of money to spend have taken a bearish stance on Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GOOGL, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 124 uncommon options trades for Alphabet.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 44%, bearish.
Out of all of the special options we uncovered, 46 are puts, for a total amount of $3,433,962, and 78 are calls, for a total amount of $7,581,492.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $350.0 for Alphabet over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Alphabet's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Alphabet's substantial trades, within a strike price spectrum from $25.0 to $350.0 over the preceding 30 days.
<h3>Alphabet Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736884836_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOOGL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$27.1</td>
<td>$26.8</td>
<td>$26.83</td>
<td>$180.00</td>
<td>$2.6M</td>
<td>1.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GOOGL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.55</td>
<td>$13.4</td>
<td>$13.46</td>
<td>$190.00</td>
<td>$807.6K</td>
<td>1.6K</td>
<td>610</td>
</tr>
<tr>
<td>GOOGL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.9</td>
<td>$11.8</td>
<td>$11.8</td>
<td>$200.00</td>
<td>$588.8K</td>
<td>20.1K</td>
<td>881</td>
</tr>
<tr>
<td>GOOGL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$30.65</td>
<td>$30.35</td>
<td>$30.5</td>
<td>$160.00</td>
<td>$228.7K</td>
<td>19.5K</td>
<td>370</td>
</tr>
<tr>
<td>GOOGL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.9</td>
<td>$11.75</td>
<td>$11.8</td>
<td>$200.00</td>
<td>$208.8K</td>
<td>20.1K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Alphabet</h3>
Alphabet is a holding company that wholly owns internet giant Google. The California-based company derives slightly less than 90% of its revenue from Google services, the vast majority of which is advertising sales. Alongside online ads, Google services houses sales stemming from Google's subscription services (YouTube TV, YouTube Music among others), platforms (sales and in-app purchases on Play Store), and devices (Chromebooks, Pixel smartphones, and smart home products such as Chromecast). Google's cloud computing platform, or GCP, accounts for roughly 10% of Alphabet's revenue with the firm's investments in up-and-coming technologies such as self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) making up the rest.
Having examined the options trading patterns of Alphabet, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Alphabet's Current Market Status</h3>
<ul>
<li>With a volume of 8,829,015, the price of GOOGL is up 0.12% at $191.24. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 14 days.</li>
</ul>
<h3>Expert Opinions on Alphabet</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $222.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wedbush has decided to maintain their Outperform rating on Alphabet, which currently sits at a price target of $220. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Alphabet, which currently sits at a price target of $225. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Alphabet, which currently sits at a price target of $225. 
&#x2A; An analyst from Wolfe Research persists with their Outperform rating on Alphabet, maintaining a target price of $230. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Alphabet with a target price of $210. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Alphabet, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

GOOGL

Unpacking the Latest Options Trading Trends in Alphabet

Investors with a lot of money to spend have taken a bullish stance on Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CORZ, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 12 options trades for Core Scientific.
This isn't normal.
The overall sentiment of these big-money traders is split between 58% bullish and 41%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $63,625, and 11, calls, for a total amount of $488,587.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $8.0 and $17.0 for Core Scientific, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Core Scientific's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Core Scientific's substantial trades, within a strike price spectrum from $8.0 to $17.0 over the preceding 30 days.
<h3>Core Scientific Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736884831_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.92</td>
<td>$1.91</td>
<td>$1.92</td>
<td>$17.00</td>
<td>$96.0K</td>
<td>4.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$8.55</td>
<td>$8.45</td>
<td>$8.45</td>
<td>$8.00</td>
<td>$66.7K</td>
<td>4.9K</td>
<td>489</td>
</tr>
<tr>
<td>CORZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.6</td>
<td>$2.42</td>
<td>$2.56</td>
<td>$12.00</td>
<td>$63.6K</td>
<td>1.0K</td>
<td>250</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$8.0</td>
<td>$7.7</td>
<td>$7.95</td>
<td>$8.00</td>
<td>$48.5K</td>
<td>4.9K</td>
<td>1.2K</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.3</td>
<td>$8.00</td>
<td>$44.4K</td>
<td>4.9K</td>
<td>72</td>
</tr>
</tbody>
</table>

<h3>About Core Scientific</h3>
Core Scientific Inc is engaged in Blockchain and AI Infrastructure, Digital Asset Self-Mining, Premium Hosting, Blockchain Technology, and Artificial Intelligence related services. The business operates in two segments being; Equipment Sales and Hosting which consists of blockchain infrastructure, third-party hosting business and equipment sales to customers. Mining segment consists of digital asset mining for its account. The blockchain business generates revenue from the sale of consumption-based contracts and by providing hosting services. The digital asset mining segment earns revenue from operating a firm's owned computer equipment as part of a pool of users that process transactions conducted on one or more blockchain networks. In exchange, it receives digital currency assets.
After a thorough review of the options trading surrounding Core Scientific, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Core Scientific's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 5,108,950, the CORZ's price is up by 3.31%, now at $14.05. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 56 days.</li>
</ul>
<h3>What Analysts Are Saying About Core Scientific</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $20.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from BTIG continues to hold a Buy rating for Core Scientific, targeting a price of $20. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Core Scientific, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Core Scientific, Inc. - Class A Common Stock

CORZ

Smart Money Is Betting Big In CORZ Options

Deep-pocketed investors have adopted a bearish approach towards Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SHEL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Shell. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 23% leaning bullish and 38% bearish. Among these notable options, 5 are puts, totaling $200,150, and 8 are calls, amounting to $359,646.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $65.0 to $72.5 for Shell during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Shell's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Shell's whale activity within a strike price range from $65.0 to $72.5 in the last 30 days. 
<h3>Shell 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736884827_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHEL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.65</td>
<td>$2.6</td>
<td>$2.6</td>
<td>$65.00</td>
<td>$82.6K</td>
<td>1.7K</td>
<td>0</td>
</tr>
<tr>
<td>SHEL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.45</td>
<td>$0.4</td>
<td>$0.4</td>
<td>$66.00</td>
<td>$68.0K</td>
<td>4.3K</td>
<td>808</td>
</tr>
<tr>
<td>SHEL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.0</td>
<td>$1.75</td>
<td>$1.8</td>
<td>$70.00</td>
<td>$54.1K</td>
<td>1.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>SHEL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$2.0</td>
<td>$1.8</td>
<td>$1.8</td>
<td>$70.00</td>
<td>$53.8K</td>
<td>1.7K</td>
<td>661</td>
</tr>
<tr>
<td>SHEL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.95</td>
<td>$1.8</td>
<td>$1.8</td>
<td>$70.00</td>
<td>$48.7K</td>
<td>1.7K</td>
<td>1.8K</td>
</tr>
</tbody>
</table>

<h3>About Shell</h3>
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 1.5 million barrels of liquids and 7.3 billion cubic feet of natural gas per day. At end-2023, reserves stood at 9.6 billion barrels of oil equivalent, 49% of which, consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.6 mmb/d located in the Americas, Asia, Africa, and Europe and sells about 12 million tons per year of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
<h3>Shell's Current Market Status</h3>
<ul>
<li>With a volume of 2,745,244, the price of SHEL is up 1.49% at $65.93. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 16 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Shell, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

SHEL

Shell Unusual Options Activity For January 14

In the last three months, 5 analysts have published ratings on Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Oshkosh and provided 12-month price targets. The average target is $125.2, accompanied by a high estimate of $160.00 and a low estimate of $110.00. Highlighting a 5.58% decrease, the current average has fallen from the previous average price target of $132.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1736884827_0_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Oshkosh by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$116.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Steven Fisher</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$125.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Mircea Dobre</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$171.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Oshkosh. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Oshkosh compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Oshkosh's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Oshkosh's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OSK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Oshkosh analyst ratings.</a>
<h2>Get to Know Oshkosh Better</h2>
Oshkosh is the top producer of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, where it is typically the market share leader in North America, or, in the case of JLG aerial work platforms, a global leader. The company had manufactured joint light tactical vehicles for the us Department of Defense. However, Oshkosh recently lost the JLTV recompete, bringing into focus its us Postal Service contract, which calls for the electrification of us postal vehicles. The company reports in three segments—access equipment (52% of revenue), defense (22%), and vocational (27%)—and generated $9.6 billion in revenue in 2023.
<h3>Financial Milestones: Oshkosh's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Oshkosh displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 9.22%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.58%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Oshkosh's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.49%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Oshkosh's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.84% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Oshkosh's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.37.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Oshkosh: 5 Analysts Share Their Views

Throughout the last three months, 11 analysts have evaluated WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated WR Berkley and provided 12-month price targets. The average target is $64.82, accompanied by a high estimate of $76.00 and a low estimate of $50.00. Surpassing the previous average price target of $62.67, the current average has increased by 3.43%.
<img src="https://www.benzinga.com/files/images/story/2025/1736884815_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive WR Berkley is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$50.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Cox</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$69.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$63.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$58.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>David Motemaden</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$60.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to WR Berkley. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of WR Berkley compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for WR Berkley's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of WR Berkley's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/WRB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on WR Berkley analyst ratings.</a>
<h2>Get to Know WR Berkley Better</h2>
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.
<h3>Breaking Down WR Berkley's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: WR Berkley's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.57%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: WR Berkley's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 10.83%, the company may face hurdles in effective cost management.
Return on Equity (ROE): WR Berkley's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 4.51%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): WR Berkley's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.92%, the company may face hurdles in achieving optimal financial returns.
Debt Management: WR Berkley's debt-to-equity ratio stands notably higher than the industry average, reaching 0.34. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where WR Berkley Stands With Analysts

ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) has outperformed the market over the past 10 years by 20.72% on an annualized basis producing an average annual return of 31.9%. Currently, ServiceNow has a market capitalization of $213.24 billion. 
Buying $100 In NOW: If an investor had bought $100 of NOW stock 10 years ago, it would be worth $1,594.26 today based on a price of $1033.56 for NOW at the time of writing.
<h3>ServiceNow's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736884810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $100 Invested In ServiceNow 10 Years Ago Would Be Worth Today

Needham analyst Chris Pierce maintains Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) with a Buy and maintains $66 price target.

Price Target

BLBD

Needham Maintains Buy on Blue Bird, Maintains $66 Price Target

Seaport analyst Jeff Cantwell downgraded Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) to Neutral from Buy rating, <a target="_blank" href="https://www.benzinga.com/quote/MA/analyst-ratings" rel="noreferrer noopener">with a price target of $521</a>.
The analyst writes that he continues to like Mastercard&#8217;s story but views the shares as fairly valued at this point.
Revenue upside in 2025 appears more limited due to its higher international exposure compared to Visa, and Mastercard lacks an identifiable catalyst, adds the analyst.
Last year, the analyst favored Mastercard over Visa. However, this year, the analyst prefers Visa relative to Mastercard, highlighting that Visa&#8217;s volumes and revenue are more U.S.-centric, where expectations are rising, while Mastercard is more exposed to international markets, which face greater risks to PCE growth.
Related: <a target="_blank" href="https://www.benzinga.com//node/42986061" rel="noreferrer noopener">This Analyst Prefers Visa Over Mastercard In 2025 &#8211; Here&#8217;s Why</a>
Additionally, with Mastercard&#8217;s Investor Day already passed, the analyst doesn&#8217;t see any identifiable catalysts for the stock this year.
Cantwell says that with the upcoming administration change in the U.S., 2025 is expected to be fluid, requiring investors to stay vigilant.
Potential policy adjustments could impact consumer and business spending, and factors like FX, inflation, and the Fed&#8217;s rate cuts further complicate the outlook, adds the analyst.
The analyst foresees a higher potential for earnings surprises in Fintech this year compared to previous years.
Investors can gain exposure to the stock via Principal Exchange-Traded Funds Principal Focused Blue Chip ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BCHP#BATS">BCHP</a>) and iShares U.S. Financial Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>).
Price Action: MA shares are up 0.78% at $508.83 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42971921/mastercard-vs-visa-bearish-trends-bullish-hopes" target="_blank" rel="noreferrer noopener">Mastercard Vs. Visa: Technical Challenges Ahead Of Earnings Showdown</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

Large Cap

Downgrades

BCHP

iShares Trust Dow Jones US Financial Services Index Fund

Mastercard Is Fairly Valued And Lacks An Identifiable Catalyst; Analyst Downgrades Stock

BofA Securities analyst Michael Feniger upgraded PACCAR Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) to Buy from Neutral, raising the <a target="_blank" href="https://www.benzinga.com/quote/PCAR/analyst-ratings" rel="noreferrer noopener">price forecast to $121.50 from $116.</a>
The analyst notes that PACCAR stock underperformed in 2024 due to pricing and production concerns, but projects green shoots in the truck market in 2025, leading to growth in 2026.
Per Feniger, PACCAR is one of the few OEMs likely to report a new peak EPS next year.
The analyst suggests that while all machinery markets face supply-demand imbalances, trucks will likely balance first due to factors like pre-emptive purchases ahead of emissions changes, stabilizing used truck inventories, and improving market indicators.
However, Feniger writes that risks include new admin pushing out EPA277, customers already replenishing fleets, weakening medium-duty orders, or higher rates impacting vocational demand.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42983278/google-stock-boosted-by-ai-growth-cloud-expansion-and-cost-discipline-despite-doj-and-generative-ai-challenges-analyst" rel="noreferrer noopener">Google Stock Boosted By AI Growth, Cloud Expansion, Cost Discipline Despite DOJ And Generative AI Challenges: Analyst</a>
The analyst notes that third-party industry forecasts predict truck builds will decline by 3% in 2025 before rising by 11% to 353.5k units in 2026. Feniger projects the company to report a new peak EPS of $10.25 in 2026, which is $1 above consensus, as freight conditions improve and customers buy trucks ahead of EPA27.
Additionally, the company&#8217;s dividend is projected to yield over 5% in 2026, the highest in the sector, offering an attractive return amid rising 10-year yields.
Price Action: PCAR shares are trading higher by 2.14% to $110.48 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42982982/when-youre-18-get-out-shaq-told-his-three-sons-he-needs-a-hedge-fund-operator-and-a-ceo-not-another-basketball-player" target="_blank" rel="noreferrer noopener">&#8216;When You&#8217;re 18, Get Out&#8217; – Shaq Told His Three Sons, He Needs A Hedge Fund Operator And A CEO, Not Another Basketball Player</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Upgrades

General

PCAR

PACCAR To Generate Over 5% Dividend Yield In 2026, Analyst Sees New Peak EPS

On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) announced multiple program updates, including:
<ul>
<li>In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor / deutivacaftor), a once-daily triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is <a href="https://www.benzinga.com/pressreleases/24/12/b42628470/vertex-announces-us-fda-approval-of-alyftrek-a-once-daily-next-in-class-cftr-modulator-for-the-tre" target="_blank" rel="noreferrer noopener">responsive to ALYFTREK</a>. Vertex raised its CF patient estimates across major markets to 94,000, while reimbursement arrangements are expected to broaden treatment access for <a href="https://www.benzinga.com/pressreleases/25/01/b42935907/vertex-provides-pipeline-and-business-updates-in-advance-of-upcoming-investor-meetings" target="_blank" rel="noreferrer noopener">10,000 eligible individuals</a>.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42652152/vertex-pharmaceuticals-alyftrek-is-an-accretive-opportunity-on-top-and-bottom-lines-say-bullish-analyst" rel="noreferrer noopener">Vertex Pharmaceuticals: Alyftrek Is An ‘Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst</a>
<ul>
<li>In December, Vertex's CASGEVY gained regulatory approval in the UAE for sickle cell disease and transfusion-dependent beta-thalassemia.</li>
<li>Suzetrigine for moderate-to-severe acute pain awaits an FDA decision by January 30, 2025, under Priority Review. This non-opioid candidate aligns with the newly effective NOPAIN Act, potentially improving pain management alternatives <a href="https://www.benzinga.com/24/12/42599745/why-is-vertex-pharmaceuticals-stock-trading-on-thursday-lower-after-back-pain-trial-data" target="_blank" rel="noreferrer noopener">and ensuring Medicare support</a>.</li>
<li>In type 1 diabetes, zimislecel entered Phase 3 trials targeting 125,000 patients. Complementary therapies, including encapsulated islet cells in VX-264, are advancing, with pivotal data expected in 2025.</li>
</ul>
RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who stopped using other CFTR modulators and many currently on existing treatments will switch to this next-gen therapy.
RBC analyst Brian Abrahams writes that in acute pain, Suzetrigine pricing may be higher than anticipated, as the company emphasized that it doesn't want to risk the long-term value of its pain portfolio or the success in chronic pain just for quick approval of its first drug. The analyst also noted that formulary placement and payer discussions will affect the initial launch.
RBC Capital maintains a Neutral rating on Vertex.
Goldman Sachs analyst Salveen Richter writes suzetrigine could become the first non-opioid treatment for acute pain approved in over 20 years.
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as income from Casgevy remains low in the near term, helping to diversify <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42396975/vertex-has-5-billion-plus-opportunity-in-pain-and-kidney-disease-programs-analyst-upgrades-stock" rel="noreferrer noopener">its commercial portfolio</a>.
Price Action: VRTX stock is down 0.46% at $411.47 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/42982029/emcor-expands-southeast-footprint-with-865-million-miller-electric-deal" target="_blank" rel="noreferrer noopener">EMCOR Expands Southeast Footprint With $865 Million Miller Electric Deal</a></li>
</ul>
Image via Vertex Pharmaceuticals

Biotech

Health Care

VRTX

Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials

Welltower's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) short percent of float has fallen 6.64% since its last report. The company recently reported that it has 9.44 million shares sold short, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Welltower Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736883921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Welltower has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Welltower's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Welltower's peer group average for short interest as a percentage of float is 7.71%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

WELL

(WELL) - Analyzing Welltower's Short Interest

Sysco's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) short percent of float has fallen 5.65% since its last report. The company recently reported that it has 13.80 million shares sold short, which is 3.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sysco Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736883915_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sysco has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Sysco's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sysco's peer group average for short interest as a percentage of float is 4.05%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Sysco?

Tetra Tech's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTEK#NYSE">TTEK</a>) short percent of float has risen 5.17% since its last report. The company recently reported that it has 5.15 million shares sold short, which is 2.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.11 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tetra Tech Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736883910_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tetra Tech has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tetra Tech's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tetra Tech's peer group average for short interest as a percentage of float is 3.43%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TTEK

How Is The Market Feeling About Tetra Tech?

TRAK

Repositrak And UpShop Entered Into A Partnership

Billed as a free speech haven, video-sharing platform Rumble Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) has always offered an interesting, albeit <a href="https://www.benzinga.com/topic/rumble">somewhat controversial business</a>. 
From an investment perspective, however, RUM stock has been unambiguously choppy. Further, the security features a negative bias. Nevertheless, under extreme selling pressure, behavioral dynamics shift from fear to greed, making Rumble an enticingly speculative wager.
Last month, the social media specialist inked a <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42650642/rumble-stock-is-ripping-higher-monday-whats-going-on">strategic investment deal</a> with a blockchain enterprise. That announcement quickly skyrocketed RUM stock. Soon enough, though, questions emerged about the <a href="https://www.benzinga.com/quote/RUM/earnings">valuation</a> of the underlying company. The business doesn't generate earnings and its sales growth has noticeably slowed in recent quarters. Not surprisingly, investors took issue with the heightened risk profile and bailed out.
The results have been ugly, to say the least. For the business week ending Jan. 10 (comparing Monday's open to Friday's close), RUM stock lost 19.65%. At the time of writing, it's down more than 6% as the bulls desperately attempt to cling to the $10 support level. Still, once this week's tug-of-war is in the books, there may be a solid chance that RUM stages a recovery attempt.
<h2 class="wp-block-heading">Behavioral Shifts Under Pressure Bode Well for RUM Stock</h2>
As stated earlier, RUM stock features a negative bias. For example, on a sequential week-to-week basis, there's about a 47% chance that an investor will see a positive return. When viewed on a four-week basis, the odds of a positive return dip slightly to 46%. Therefore, without any other context, it's best to avoid excessive long exposure to Rumble stock.
However, this framework changes dramatically when the security faces substantial selling pressure or extreme fear. Statistically, following a one-week loss of 10% or greater, RUM stock tends to rise by the end of the fourth subsequent week, with the odds of a positive return reaching 66.7%.
To be fair, applying conditional or dynamic probabilities dramatically limits the size of the dataset. Nevertheless, a clear trend can be established. Historically, whenever RUM stock lost any value for the week, the chances of the conclusion of the fourth subsequent week posting a positive return rises to 50.5%. For 5% losses or worse, the stats improve to 53.5%. Thus, the greater the loss, the greedier the market becomes.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14140731/Probability-gambit-RUM-stock-1024x576.jpg" alt="" class="wp-image-733263" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14140731/Probability-gambit-RUM-stock-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14140731/Probability-gambit-RUM-stock-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14140731/Probability-gambit-RUM-stock-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14140731/Probability-gambit-RUM-stock.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Notably, the fourth subsequent week following a 10% weekly drop produces a median return of 8.68% when the response itself is positive. However, in the third week, the median positive return soars to 27.83%. For whatever reason, the bulls historically wait until the third week following an extreme-fear event before placing their chips on the table.
It's also worth noting that the first week following an extreme-fear event offers no predictive insight. Therefore, traders may consider sitting out the current week.
<h2 class="wp-block-heading">Several Call Spread Ideas Beckon</h2>
Using last Friday's closing price of $10.96 as an anchor point, traders can plot their options strategies. Arguably the most aggressive trade available will target the third week following a 10% weekly loss. Given the median positive return of 27.83%, RUM stock could possibly reach $14.01 by the options chain expiring Jan. 31. Interestingly, this target corresponds with a key technical resistance level.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14140643/RUM-stock-01142025-1024x591.jpg" alt="" class="wp-image-733262" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14140643/RUM-stock-01142025-1024x591.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14140643/RUM-stock-01142025-300x173.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14140643/RUM-stock-01142025-768x443.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/14140643/RUM-stock-01142025.jpg 1027w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
To no surprise, market makers are currently offering gargantuan payouts for <a href="https://www.benzinga.com/money/bull-spread">bull call spreads</a> with the short (second leg) strike price of $14. At the moment, the biggest payout stems from the 12.50/14.00 call spread (buy the $12.50 call, simultaneously sell the $14 call).
On any given three-week period, RUM stock features a median positive return of 7.01%. This stochastic projection implies an upside target of $11.74. More conservative speculators could potentially split the difference between stochastic and dynamic price projections and aim for a bull call spread (again expiring Jan. 31) that features a short leg strike of $12.50.
Finally, traders who want to wait out the early noise in RUM stock may target the options chain expiring Feb. 7. Here, the dynamic price projection calls for an 8.68% median positive return, meaning that RUM may reach $11.91. In that case, an 11/12 bull call spread offers a big payout and a relatively lengthy runway for the hypothesis to pan out.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/01/42986605/exclusive-energy-semiconductors-could-dominate-portfolios-in-2025-says-direxion-ceo">EXCLUSIVE: Energy, Semiconductors Could Dominate Portfolios In 2025, Says Direxion CEO</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Social Media

Movers

Options Corner: Wait Out Rumble's Choppiness Before Diving In

Netcapital Inc. (NCPL) Q3 2024 Earnings Call Transcript

Netcapital Inc. (NCPL) Q4 2024 Earnings Call Transcript

NCPL

NCPLW

Press Releases

Netcapital Announces Intention to Complete a Reverse Stock Split at Special Stockholder Meeting

Netcapital Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Netcapital Announces Launch of Beta Version for Secondary Trading Platform

Netcapital Announces Full Year Fiscal 2024 Financial Results

Netcapital Announces 1-for-70 Reverse Stock Split

Netcapital to Present at H.C. Wainwright 26th Annual Global Investment Conference

Netcapital Announces First Quarter Fiscal 2025 Financial Results

Netcapital Secures FINRA Approval for Broker-Dealer License

Netcapital Announces Second Quarter Fiscal 2025 Financial Results

Netcapital Announces Exercise of Warrants

Affiliated Managers Group, Inc. Common Stock

Affiliated Managers Group

Ameriprise Finl

Ares Capital Corporation - Closed End Fund

Ares Capital

Ares Management Corporation Class A Common Stock

Ares Management

Franklin Resources

The Bank of New York Mellon Corporation Common Stock

Bank of New York Mellon

BlackRock

Brookfield Corporation Class A Limited Voting Shares

Brookfield

Blackstone

Blackstone Secured Lending Fund Common Shares of Beneficial Interest

Blackstone Secured

Carlyle Group

Cohen & Steers

FS KKR Capital

Hamilton Lane Incorporated - Class A Common Stock

Hamilton Lane

Invesco

Janus Henderson Group plc Ordinary Shares

Janus Henderson Group

Main Street Capital Corporation Common Stock

Main Street Capital

Netcapital

Northern Trust Corporation - Common Stock

Northern Trust

Blue Owl Capital Corporation Common Stock

Blue Owl Capital

Blue Owl Capital Inc. Class A Common Stock

Blue Owl Cap

SEI Inv

StepStone Group Inc. - Class A Common Stock

Comments

Netcapital

News

Latest news for Netcapital (NASDAQ:NCPLW) Stock

Friday, August 02, 2024

Thursday, August 01, 2024

People Also Watch

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga